Showing 621 - 640 results of 14,709 for search '(( 50 ms decrease ) OR ( 50 ((((nn decrease) OR (we decrease))) OR (mean decrease)) ))', query time: 0.53s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624

    Shape-Based Reprofiling of FDA-Approved Drugs for the H<sub>1</sub> Histamine Receptor by Sridhar R. Vasudevan (589877)

    Published 2012
    “…Reprofiling of existing drugs to treat conditions not originally targeted is an attractive means of addressing the problem of a decreasing stream of approved drugs. …”
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633
  14. 634
  15. 635
  16. 636
  17. 637
  18. 638
  19. 639

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  20. 640

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”